| __timestamp | Axsome Therapeutics, Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4279200 | 51796000 |
| Thursday, January 1, 2015 | 6776987 | 72758000 |
| Friday, January 1, 2016 | 21199860 | 61008000 |
| Sunday, January 1, 2017 | 19957616 | 66962000 |
| Monday, January 1, 2018 | 23495055 | 84888000 |
| Tuesday, January 1, 2019 | 53647067 | 107068000 |
| Wednesday, January 1, 2020 | 70244579 | 122964000 |
| Friday, January 1, 2021 | 58060725 | 208808000 |
| Saturday, January 1, 2022 | 57947447 | 253297000 |
| Sunday, January 1, 2023 | 97944000 | 216566000 |
| Monday, January 1, 2024 | 187077000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, innovation is key. Axsome Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. have been at the forefront of this race, investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, BioCryst consistently outpaced Axsome, with R&D expenses peaking at over 250% higher in 2022. However, Axsome has shown remarkable growth, increasing its R&D spending by over 2,000% from 2014 to 2023. This surge reflects Axsome's commitment to advancing its pipeline and potentially closing the gap with BioCryst. As both companies continue to innovate, investors and stakeholders are keenly watching who will lead the next wave of breakthroughs in the biotech industry.
Analyzing R&D Budgets: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
R&D Spending Showdown: Vertex Pharmaceuticals Incorporated vs Axsome Therapeutics, Inc.
Research and Development Investment: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Axsome Therapeutics, Inc.
Research and Development Expenses Breakdown: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Axsome Therapeutics, Inc. vs Xencor, Inc.
Research and Development Investment: Axsome Therapeutics, Inc. vs Novavax, Inc.
ADMA Biologics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Catalyst Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Galapagos NV vs BioCryst Pharmaceuticals, Inc.
Research and Development Investment: BioCryst Pharmaceuticals, Inc. vs MiMedx Group, Inc.